Prenatal Testing Can Detect Cancer in Mothers
By HospiMedica International staff writers Posted on 26 Jul 2015 |
A new study suggests that noninvasive prenatal testing (NIPT) for genetic anomalies could identify occult, previously undiagnosed maternal malignancies.
Researchers at Tufts University Medical Center (Boston, MA, USA), the Dana-Farber Cancer Institute (Boston, MA, USA), and other institutions analyzed 125,426 samples submitted between February 15, 2012, and September 30, 2014, from asymptomatic pregnant women who underwent NIPT screening for fetal aneuploidy (chromosomes 13, 18, 21, X, and Y). Abnormal results were detected in 3,757 (3%) of samples; these were reported to the ordering physician with recommendations for further evaluation.
The results showed that from the set of 3,757 aneuploidy samples, 10 cases of maternal cancer were identified. Detailed clinical and sequencing data were obtained in eight of the women. The researchers found that maternal cancers most frequently occurred when an NIPT finding of more than one aneuploidy was detected. All eight cases that underwent further bioinformatics analysis showed unique patterns of nonspecific copy-number gains and losses across multiple chromosomes. In one case, blood was sampled after completion of treatment for colorectal cancer and the abnormal pattern was no longer evident. The study was published on July 14, 2015, in JAMA.
“If someone has cancer, the tumor itself is shedding DNA in the mother's blood. The test is picking up excess amounts of DNA from particular chromosomes. It's kind of an accident in a way that the test is picking up the DNA from the tumor,” said lead author medical geneticist Diana Bianchi, MD, executive director of the Mother Infant Research Institute at Tufts Medical Center. “The take-home message is that women should be aware of this possibility when they seek testing. It doesn't necessarily mean anything is wrong with the fetus.”
NIPT is a screening test that analyzes the mother's blood and contains fragments of both placental and maternal DNA. Certain fetal abnormalities are associated with specific chromosomes and may indicate birth defects or a condition such as Down's syndrome. NIPT can be done as early as the 10th week of pregnancy, and is typically offered to women with high-risk pregnancies, such as older mothers or those with a family history of certain birth defects.
Related Links:
Tufts University Medical Center
Dana-Farber Cancer Institute
Researchers at Tufts University Medical Center (Boston, MA, USA), the Dana-Farber Cancer Institute (Boston, MA, USA), and other institutions analyzed 125,426 samples submitted between February 15, 2012, and September 30, 2014, from asymptomatic pregnant women who underwent NIPT screening for fetal aneuploidy (chromosomes 13, 18, 21, X, and Y). Abnormal results were detected in 3,757 (3%) of samples; these were reported to the ordering physician with recommendations for further evaluation.
The results showed that from the set of 3,757 aneuploidy samples, 10 cases of maternal cancer were identified. Detailed clinical and sequencing data were obtained in eight of the women. The researchers found that maternal cancers most frequently occurred when an NIPT finding of more than one aneuploidy was detected. All eight cases that underwent further bioinformatics analysis showed unique patterns of nonspecific copy-number gains and losses across multiple chromosomes. In one case, blood was sampled after completion of treatment for colorectal cancer and the abnormal pattern was no longer evident. The study was published on July 14, 2015, in JAMA.
“If someone has cancer, the tumor itself is shedding DNA in the mother's blood. The test is picking up excess amounts of DNA from particular chromosomes. It's kind of an accident in a way that the test is picking up the DNA from the tumor,” said lead author medical geneticist Diana Bianchi, MD, executive director of the Mother Infant Research Institute at Tufts Medical Center. “The take-home message is that women should be aware of this possibility when they seek testing. It doesn't necessarily mean anything is wrong with the fetus.”
NIPT is a screening test that analyzes the mother's blood and contains fragments of both placental and maternal DNA. Certain fetal abnormalities are associated with specific chromosomes and may indicate birth defects or a condition such as Down's syndrome. NIPT can be done as early as the 10th week of pregnancy, and is typically offered to women with high-risk pregnancies, such as older mothers or those with a family history of certain birth defects.
Related Links:
Tufts University Medical Center
Dana-Farber Cancer Institute
Latest Patient Care News
- First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds
- Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization
- Game-Changing Innovation in Surgical Instrument Sterilization Significantly Improves OR Throughput
- Next Gen ICU Bed to Help Address Complex Critical Care Needs
- Groundbreaking AI-Powered UV-C Disinfection Technology Redefines Infection Control Landscape
- Clean Hospitals Can Reduce Antibiotic Resistance, Save Lives
- Smart Hospital Beds Improve Accuracy of Medical Diagnosis
- New Fast Endoscope Drying System Improves Productivity and Traceability
- World’s First Automated Endoscope Cleaner Fights Antimicrobial Resistance
- Portable High-Capacity Digital Stretcher Scales Provide Precision Weighing for Patients in ER
- Portable Clinical Scale with Remote Indicator Allows for Flexible Patient Weighing Use
- Innovative and Highly Customizable Medical Carts Offer Unlimited Configuration Possibilities
- Biomolecular Wound Healing Film Adheres to Sensitive Tissue and Releases Active Ingredients
- Wearable Health Tech Could Measure Gases Released From Skin to Monitor Metabolic Diseases
- Wearable Cardioverter Defibrillator System Protects Patients at Risk of Sudden Cardiac Arrest
- World's First AI-Ready Infrasound Stethoscope Listens to Bodily Sounds Not Audible to Human Ear